UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or...
American Oriental Bioengineering Inc. Announces Plans for Reverse Stock Split of its Common Stock PR Newswire NEWARK, N.J., Feb. 21, 2012 NEWARK...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the...
We reiterate our Neutral recommendation on American Oriental Bioengineering, Inc. (AOB) with a target price of $0.75. The company recently...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION...
American Oriental Bioengineering’s (AOB) third quarter 2011 earnings (excluding the gain on debt extinguishment) came in at 7 cents per...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 10-Q (Mark One...
American Oriental Bioengineering Reports Third Quarter 2011 Financial Results PR Newswire JERSEY CITY, N.J., Nov. 14, 2011 JERSEY CITY, N.J...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A Amendment No. 1 ...
American Oriental Bioengineering to Hold Third Quarter 2011 Earnings Conference Call at 8:00 AM on November 15, 2011 PR Newswire JERSEY CITY...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly report...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
News
Market Data
Register to chat with like-minded investors on our interactive forums.
